Christopher J. Schultz, MD

Christopher J. Schultz, MD, FACR, FASTRO

Chair and Bernard & Miriam Peck Family Professor of Radiation Oncology

Locations

Radiation Oncology

Contact Information

(414) 805-4472

Education

1985, Medical College of Wisconsin, MD

Biography

Training

Residency Radiation Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI (1989-1990)

Residency Radiation Oncology, Presbyterian Hospital, New York, NY (1986-1988)

Internship Children's Mercy Hospital, Kansas City, MO (1985-1986)

Certifications

Recertification, Radiation Oncology, American Board of Radiology (2000)

Board Certification, Radiation Oncology, American Board of Radiology (1990)

Patient Care Emphases

Head and neck cancer
Hodgkin's Disease
Low dose rate irradiation
Gamma Knife stereotactic radiosurgery
Lymphoma
Brain tumors

View Provider Profile

Salvage of Recurrence after Surgery and Adjuvant Therapy: A Multi-institutional Study.

(Zenga J, Graboyes E, Janz T, Drake V, Rettig E, Desai S, Nickel C, Shabani S, Padhya T, Scarpinato M, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P.) Otolaryngol Head Neck Surg. 2019 Jul;161(1):74-81.
Lymph node yield from neck dissection in HPV-associated oropharyngeal cancer.

(Zenga J, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P.) Laryngoscope. 2019 Jun 17.
Serial T2-Weighted Magnetic Resonance Images Acquired on a 1.5 Tesla Magnetic Resonance Linear Accelerator Reveal Radiomic Feature Variation in Organs at Risk: An Exploratory Analysis of Novel Metrics of Tissue Response in Prostate Cancer.

(Lorenz JW, Schott D, Rein L, Mostafaei F, Noid G, Lawton C, Bedi M, Li XA, Schultz CJ, Paulson E, Hall WA.) Cureus. 2019 Apr 20;11(4):e4510.
Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.

(Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ Jr, Werner-Wasik M, Smith RP, Schultz C, Hartford AC, Zhang P, Mehta MP.) Int J Radiat Oncol Biol Phys. 2019 03 15;103(4):878-886.
Early Prediction of Acute Xerostomia During Radiation Therapy for Head and Neck Cancer Based on Texture Analysis of Daily CT.

(Wu H, Chen X, Yang X, Tao Y, Xia Y, Deng X, Zheng C, Robbins J, Schultz C, Li XA.) Int J Radiat Oncol Biol Phys. 2018 11 15;102(4):1308-1318.
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.

(Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A.) JAMA Oncol. 2018 10 01;4(10):1405-1409.
Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order.

(Bovi JA, Schultz CJ, Mehta MP, Corn BW.) Int J Radiat Oncol Biol Phys. 2018 09 01;102(1):59-60.
Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference.

(Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY.) Int J Radiat Oncol Biol Phys. 2018 06 01;101(2):274-284.
Current Predictive Indices and Nomograms To Enable Personalization of Radiation Therapy for Patients With Secondary Malignant Neoplasms of the Central Nervous System: A Review.

(Gilbride L, Siker M, Bovi J, Gore E, Schultz C, Hall WA.) Neurosurgery. 2018 05 01;82(5):595-603.
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.

(Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN, Michalski JM, Fischbach AJ, Markoe AM, Schultz CJ, Penas-Prado M, Garg MK, Hartford AC, Kim HE, Won M, Curran WJ Jr.) J Neurooncol. 2018 Mar;137(1):39-47.
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

(Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M.) Neuro Oncol. 2017 02 01;19(2):252-258.
R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology.

(Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, Mook S, Sahgal A, Hall E, Schultz C.) Front Oncol. 2017;7:59.